Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.74 |
| ▸ | BLM | P54132 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.41 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.31 |
| ▸ | CDC25B | P30305 | 1/20 | 0.31 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.30 |
| ▸ | FNTA | P49354 | 1/20 | 0.30 |
| ▸ | PGGT1B | P53609 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23112992 | 0.97 | LMNA (0.68) | LMNABLMMEN1CYP3A4ALOX15 | |
| SCHEMBL4290473 | 0.97 | LMNA (0.68) | LMNABLMMEN1CYP3A4ALOX15 | |
| SCHEMBL2871969 | 0.97 | LMNA (0.68) | LMNABLMMEN1CYP3A4ALOX15 | |
| SCHEMBL22615110 | 0.90 | LMNA (0.57) | LMNABLMMEN1CYP3A4ALOX15 | |
| SCHEMBL16875676 | 0.90 | LMNA (0.65) | LMNABLMMEN1CYP3A4ALOX15 | |
| SCHEMBL1282483 | 0.89 | LMNA (0.53) | LMNABLMMEN1CYP3A4ALOX15 | |
| SCHEMBL9122712 | 0.89 | — | — | |
| SCHEMBL446676 | 0.89 | — | — | |
| SCHEMBL3267924 | 0.86 | LMNA (0.50) | LMNABLMMEN1CYP3A4ALOX15 | |
| SCHEMBL3883339 | 0.86 | LMNA (0.50) | LMNABLMMEN1CYP3A4ALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1753708-B1 | NOVEL SIRTUIN ACTIVATING COMPOUNDS AND METHODS FOR MAKING THE SAME | UNIV BRIGHAM YOUNG (US) | 2018-02-21 | — | — | EP | claimed |
| WO-2024108186-A2 | PRODUCTION OF HYDROGEN FROM CARBOHYDRATES USING VIOLOGEN CATALYSTS | WATT POWER INC. (US) | 2024-05-23 | — | — | WO | disclosed |
| US-9980937-B2 | Therapeutic agent for Alzheimer's disease | NAGASAKI UNIVERSITY (JP) | 2018-05-29 | — | — | US | disclosed |
| EP-1753708-B1 | NOVEL SIRTUIN ACTIVATING COMPOUNDS AND METHODS FOR MAKING THE SAME | UNIV BRIGHAM YOUNG (US) | 2018-02-21 | — | — | EP | disclosed |
| US-20170252318-A1 | NOVEL THERAPEUTIC AGENT FOR ALZHEIMER'S DISEASE | NAGASAKI UNIVERSITY (JP) | 2017-09-07 | — | — | US | disclosed |
| US-8841477-B2 | Sirtuin activating compounds and processes for making the same | BRIGHAM YOUNG UNIVERSITY (US) | 2014-09-23 | — | — | US | disclosed |
| US-8404396-B2 | Fuel cell and method for generating electric power | BRIGHAM YOUNG UNIVERSITY (US) | 2013-03-26 | — | — | US | disclosed |
| US-20100185006-A1 | NOVEL SIRTUIN ACTIVATING COMPOUNDS AND PROCESSES FOR MAKING THE SAME | BRIGHAM YOUNG UNIVERSITY (US) | 2010-07-22 | — | — | US | disclosed |
| US-20100151356-A1 | FUEL CELL AND METHOD FOR GENERATING ELECTRIC POWER | BRIGHAM YOUNG UNIVERSITY (US) | 2010-06-17 | — | — | US | disclosed |
| US-7714161-B2 | N-heterocyclic carbon-type ligand coupling in the presence of a base with benzyol halide and styrene coupling partners; resveratrol; increased stability for use in the food, cosmetic and pharmaceutical industries | BRIGHAM YOUNG UNIVERSITY (US) | 2010-05-11 | — | — | US | disclosed |
| WO-2008143877-A1 | FUEL CELL AND METHOD FOR GENERATING ELECTRIC POWER | BRIGHAM YOUNG UNIVERSITY (US) | 2008-11-27 | — | — | WO | disclosed |
| US-20080255382-A1 | N-heterocyclic carbon-type ligand coupling in the presence of a base with benzyol halide and styrene coupling partners; resveratrol; increased stability for use in the food, cosmetic and pharmaceutical industries | BRIGHAM YOUNG UNIVERSITY | 2008-10-16 | — | — | US | disclosed |
| EP-1753708-A4 | NOVEL SIRTUIN ACTIVATING COMPOUNDS AND METHODS FOR MAKING THE SAME | UNIV BRIGHAM YOUNG (US) | 2007-12-26 | — | — | EP | disclosed |
| EP-1753708-A2 | NOVEL SIRTUIN ACTIVATING COMPOUNDS AND METHODS FOR MAKING THE SAME | Brigham Young University (US) | 2007-02-21 | — | — | EP | disclosed |
| WO-2005069998-A2 | NOVEL SIRTUIN ACTIVATING COMPOUNDS AND METHODS FOR MAKING THE SAME | BRIGHAM YOUNG UNIVERSITY TECHNOLOGY TRANSFER OFFICE (US) | 2005-08-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100185006-A1 | NOVEL SIRTUIN ACTIVATING COMPOUNDS AND PROCESSES FOR MAKING THE SAME | SIRT1, SIRT2, SIRT3 | LMNA 1305/4885BLM 1162/4885MEN1 3475/4885 |
| US-20170252318-A1 | NOVEL THERAPEUTIC AGENT FOR ALZHEIMER'S DISEASE | PSEN2, BACE1, PSEN1 | LMNA 615/4885BLM 4800/4885MEN1 4480/4885 |
| US-20080255382-A1 | N-heterocyclic carbon-type ligand coupling in the presence of a base with benzyol halide and styrene coupling partners; resveratrol; increased stability for use in the food, cosmetic and pharmaceutical industries | RB1, SBK1, NADK | LMNA 1421/4885BLM 629/4885MEN1 3788/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.